Ordering
Available Variants5 mg
CHA.41483-5mg
Price
€96.00
Available – Dispatch in 14 days
25 mg
CHA.41483-25mg
Price
€320.28
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.41483-5mg | €96.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.41483-25mg | €320.28 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C17H23N5O |
|---|---|
| CAS Number | 1020412-43-4 |
| Molecular Weight | 313.40 |
| NACRES | NA.77 |
| UNSPSC Code | 51111800 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H315,H319,H335 |
| pcodes | P302 + P352 - P305 + P351 + P338 |
| Hazard Classifications | Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
| target_organs | Respiratory system |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Gardiquimod, with a CAS number of 1020412-43-4, is a synthetic Toll-like receptor 7 and 8 agonist under investigation for its potential therapeutic applications. This small molecule compound has been studied for its ability to stimulate the immune system, inducing the production of cytokines and activating various immune cells. Gardiquimods mechanism of action involves the activation of Toll-like receptors, which play a crucial role in the recognition of pathogens and the initiation of immune responses. As a result, gardiquimod has been explored as a potential treatment for various diseases, including infectious diseases and cancer. Its ability to modulate the immune system makes it an interesting candidate for further research and development, with potential applications in the fields of immunotherapy and vaccine adjuvants. Further studies are needed to fully elucidate the therapeutic potential of gardiquimod.
